Current treatment options for metastatic castration‐resistant prostate cancer

02/2018

MUDr. Aneta Rozsypalová¹, doc. MUDr. Josef Dvořák, Ph.D.¹, MUDr. Igor Richter, Ph.D.², MUDr. David Buka³, MUDr. Jana Grimová⁴, MUDr. Michaela Matoušková¹

1) Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

2) Oddělení klinické onkologie, Krajská nemocnice Liberec, a.s.

3) Klinika onkologie a radioterapie LF UK a FN Hradec Králové

4) Onkologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

Prostate cancer is mostly hormonal dependent disease from the beginning but during sometime develops in castration-resistant prostate cancer - it is time when the progression of the disease is occurring despite androgen deprivation therapy and patients have a testosterone level drawn. Many trials are interested in finding new opportunities of treatment of this stage. Thanks these trials we have new drugs: in category of cytotoxic chemotherapy cabazitaxel, new generation of androgen deprivation therapy ARTA (abirateron acetate, enzalutamide). For patients with bone-only metastatic disease, without visceral metastasis, there is an opportunity to use radium 223. And we can't forget immunotherapy agents as sipuleucel-T and check point inhibitors. So we have many opportunities which significantly prolong median of overall survival with good quality of life.

KEY WORDS

metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, abiraterone, enzalutamide, radium 223